A single-center retrospective study of dabrafenib plus trametinib combination therapy in patients with BRAF V600E-positive thyroid cancer

作者
Taiju Ando,Yuko Oya,Yumi Tomiie,Kimio Ogawa,Tomoki Kuki,Yosuke Tanabe,Hisayuki Kato,Kazuyoshi Imaizumi,Yatsuka Hibi,Kenji Kawada
出处
期刊:International Journal of Clinical Oncology [Springer Science+Business Media]
卷期号:30 (11): 2257-2265 被引量:10
标识
DOI:10.1007/s10147-025-02861-8
摘要

BACKGROUND: BRAF V600E mutation is a key oncogenic driver commonly found in papillary thyroid carcinoma (PTC) and anaplastic thyroid carcinoma (ATC). Dabrafenib plus trametinib combination therapy targeting this mutation has shown promising activity in clinical trials. This study aimed to verify the real-world effectiveness of this combination therapy in patients with BRAF V600E-positive PTC and ATC. METHODS: We retrospectively investigated adult patients with BRAF V600E-positive PTC and ATC who were treated with dabrafenib plus trametinib at a single university hospital in Japan. RESULTS: Between January 2024 and December 2024, 10 patients with PTC and 6 patients with ATC were identified, among whom 13 patients (81%) had been previously treated with lenvatinib. An objective response was observed in 5 patients with PTC (50%) and 4 patients with ATC (67%). The median progression-free survival and overall survival were not reached in patients with PTC, and were 2.7 months and 3.6 months, respectively, in patients with ATC. Partial regression of intracranial metastatic tumors was observed in 1 of the 2 patients with brain metastases at baseline. Rechallenge with another BRAF/MEK inhibitor combination therapy, encorafenib plus binimetinib, was attempted in 2 patients with ATC and demonstrated clinically meaningful responses. CONCLUSIONS: Dabrafenib plus trametinib combination therapy demonstrated clinical effectiveness in patients with BRAF V600E-positive thyroid cancer, with response rates comparable to those observed in clinical trials. However, tumor shrinkage did not appear to translate into improved survival in patients with ATC, highlighting the limitations of current targeted therapies in managing this aggressive subtype.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
ding的应助被嗷呜采纳,获得10
刚刚
司念者你完成签到 ,获得积分10
刚刚
刚刚
Young发布了新的文献求助10
刚刚
啊啊啊发布了新的文献求助10
1秒前
1秒前
Owen的应助被乐鱼采纳,获得10
1秒前
1秒前
111完成签到 ,获得积分10
1秒前
2秒前
禽兽琦完成签到,获得积分10
3秒前
hapea完成签到,获得积分10
3秒前
深情安青的应助被大意的凝芙采纳,获得20
3秒前
少年的回忆完成签到,获得积分10
3秒前
香蕉觅云的应助被小小采纳,获得10
4秒前
香蕉君达完成签到,获得积分10
4秒前
研友_8KXdRL完成签到,获得积分10
4秒前
4秒前
6秒前
一芜所有发布了新的文献求助10
6秒前
7秒前
7秒前
222完成签到 ,获得积分10
7秒前
小龚发布了新的文献求助10
7秒前
Lucas的应助被205采纳,获得10
8秒前
8秒前
8秒前
爆米花的应助被科研通管家采纳,获得10
9秒前
9秒前
在水一方的应助被科研通管家采纳,获得10
9秒前
搜集达人的应助被科研通管家采纳,获得10
9秒前
研友_VZG7GZ的应助被少年的回忆采纳,获得10
9秒前
华仔的应助被科研通管家采纳,获得10
9秒前
赘婿的应助被科研通管家采纳,获得10
9秒前
赘婿的应助被科研通管家采纳,获得10
9秒前
9秒前
英俊的铭的应助被科研通管家采纳,获得10
9秒前
发发发发的应助被科研通管家采纳,获得10
10秒前
领导范儿的应助被科研通管家采纳,获得10
10秒前
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181408
求助须知:如何正确求助?哪些是违规求助? 9571330
关于积分的说明 21817615
捐赠科研通 7777856
什么是DOI,文献DOI怎么找? 3433479
关于科研通互助平台的介绍 2557696
邀请新用户注册赠送积分活动 2479527